Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARDS NASDAQ:CPIX NASDAQ:DMAC NASDAQ:LPTX NASDAQ:SNGX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARDSAridis Pharmaceuticals$0.00-9.5%$0.00$0.00▼$0.05$101K38.3723,635 shs28,120 shsCPIXCumberland Pharmaceuticals$3.64+2.2%$3.32$1.04▼$7.25$53.26M-0.4131,037 shs27,383 shsDMACDiaMedica Therapeutics$6.62-2.2%$6.53$3.19▼$7.49$349.93M1.4236,801 shs268,094 shsLPTXLeap Therapeutics$0.49-7.1%$0.40$0.22▼$4.79$21.66M-0.057.91 million shs718,095 shsSNGXSoligenix$1.65-2.9%$2.41$1.09▼$6.23$7.29M1.952.94 million shs222,577 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARDSAridis Pharmaceuticals+950.00%+950.00%+950.00%+2,000.00%-79.00%CPIXCumberland Pharmaceuticals+3.49%+5.95%+13.02%+4.71%+184.80%DMACDiaMedica Therapeutics+2.89%-4.11%-0.73%+47.17%+55.99%LPTXLeap Therapeutics-5.24%-13.35%+80.33%+48.89%-80.46%SNGXSoligenix+3.03%-1.16%-36.80%+20.57%-56.02%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARDSAridis Pharmaceuticals$0.00-9.5%$0.00$0.00▼$0.05$101K38.3723,635 shs28,120 shsCPIXCumberland Pharmaceuticals$3.64+2.2%$3.32$1.04▼$7.25$53.26M-0.4131,037 shs27,383 shsDMACDiaMedica Therapeutics$6.62-2.2%$6.53$3.19▼$7.49$349.93M1.4236,801 shs268,094 shsLPTXLeap Therapeutics$0.49-7.1%$0.40$0.22▼$4.79$21.66M-0.057.91 million shs718,095 shsSNGXSoligenix$1.65-2.9%$2.41$1.09▼$6.23$7.29M1.952.94 million shs222,577 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARDSAridis Pharmaceuticals+950.00%+950.00%+950.00%+2,000.00%-79.00%CPIXCumberland Pharmaceuticals+3.49%+5.95%+13.02%+4.71%+184.80%DMACDiaMedica Therapeutics+2.89%-4.11%-0.73%+47.17%+55.99%LPTXLeap Therapeutics-5.24%-13.35%+80.33%+48.89%-80.46%SNGXSoligenix+3.03%-1.16%-36.80%+20.57%-56.02%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARDSAridis Pharmaceuticals 0.00N/AN/AN/ACPIXCumberland Pharmaceuticals 1.00SellN/AN/ADMACDiaMedica Therapeutics 2.50Moderate Buy$12.3386.30% UpsideLPTXLeap Therapeutics 1.75Reduce$3.38595.02% UpsideSNGXSoligenix 2.00Hold$6.00263.64% UpsideCurrent Analyst Ratings BreakdownLatest DMAC, ARDS, CPIX, LPTX, and SNGX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025CPIXCumberland PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025DMACDiaMedica TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025LPTXLeap TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025SNGXSoligenixWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025CPIXCumberland PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025DMACDiaMedica TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025LPTXLeap TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025SNGXSoligenixWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)8/15/2025DMACDiaMedica TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.00(Data available from 10/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARDSAridis PharmaceuticalsN/AN/AN/AN/AN/AN/ACPIXCumberland Pharmaceuticals$37.87M1.44$0.26 per share13.84$1.61 per share2.26DMACDiaMedica TherapeuticsN/AN/AN/AN/A$0.95 per shareN/ALPTXLeap TherapeuticsN/AN/AN/AN/A$0.91 per shareN/ASNGXSoligenix$120K58.99N/AN/A$1.64 per share1.01Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARDSAridis Pharmaceuticals-$30.37MN/A0.00∞N/AN/AN/AN/AN/ACPIXCumberland Pharmaceuticals-$6.48M-$0.22N/A∞N/A-6.97%7.48%2.66%11/6/2025 (Estimated)DMACDiaMedica Therapeutics-$24.44M-$0.69N/AN/AN/AN/A-78.99%-69.94%11/12/2025 (Estimated)LPTXLeap Therapeutics-$67.56M-$1.58N/AN/AN/AN/A-237.65%-155.38%11/12/2025 (Estimated)SNGXSoligenix-$8.27M-$3.80N/AN/AN/AN/A-274.76%-129.20%11/14/2025 (Estimated)Latest DMAC, ARDS, CPIX, LPTX, and SNGX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/14/2025Q3 2025SNGXSoligenix-$0.63N/AN/AN/AN/AN/A11/12/2025Q3 2025DMACDiaMedica Therapeutics-$0.15N/AN/AN/AN/AN/A11/12/2025Q3 2025LPTXLeap Therapeutics-$0.24N/AN/AN/AN/AN/A8/14/2025Q2 2025LPTXLeap Therapeutics-$0.29-$0.40-$0.11-$0.40N/AN/A8/14/2025Q2 2025SNGXSoligenix-$0.79-$0.82-$0.03-$0.82N/AN/A8/12/2025Q2 2025DMACDiaMedica Therapeutics-$0.18-$0.18N/A-$0.18N/AN/A8/5/2025Q2 2025CPIXCumberland PharmaceuticalsN/A$0.02N/A-$0.05N/A$10.84 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARDSAridis PharmaceuticalsN/AN/AN/AN/AN/ACPIXCumberland PharmaceuticalsN/AN/AN/AN/AN/ADMACDiaMedica TherapeuticsN/AN/AN/AN/AN/ALPTXLeap TherapeuticsN/AN/AN/AN/AN/ASNGXSoligenixN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARDSAridis PharmaceuticalsN/AN/AN/ACPIXCumberland Pharmaceuticals0.191.301.17DMACDiaMedica TherapeuticsN/A7.557.55LPTXLeap TherapeuticsN/A1.341.34SNGXSoligenixN/A1.471.47Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARDSAridis Pharmaceuticals9.65%CPIXCumberland Pharmaceuticals15.51%DMACDiaMedica Therapeutics10.12%LPTXLeap Therapeutics30.46%SNGXSoligenix3.60%Insider OwnershipCompanyInsider OwnershipARDSAridis Pharmaceuticals5.50%CPIXCumberland Pharmaceuticals44.85%DMACDiaMedica Therapeutics7.30%LPTXLeap Therapeutics7.50%SNGXSoligenix3.05%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARDSAridis Pharmaceuticals3053.32 million50.39 millionNot OptionableCPIXCumberland Pharmaceuticals8014.96 million8.25 millionOptionableDMACDiaMedica Therapeutics2051.69 million47.92 millionOptionableLPTXLeap Therapeutics4041.44 million38.33 millionOptionableSNGXSoligenix204.29 million4.16 millionNot OptionableDMAC, ARDS, CPIX, LPTX, and SNGX HeadlinesRecent News About These CompaniesSoligenix Updates United States Medical Advisory Board for Cutaneous T-Cell LymphomaOctober 14, 2025 | prnewswire.comSoligenix shares surge after safety milestone in Phase 3 CTCL trialOctober 7, 2025 | msn.comSoligenix’s HyBryte achieves safety milestone in Phase 3 T-cell lymphoma trialOctober 7, 2025 | msn.comSOLIGENIX, INC.: Soligenix Achieves Important Safety Milestone in its Confirmatory Phase 3 Clinical Trial of HyBryte for the Treatment of Cutaneous T-Cell LymphomaOctober 7, 2025 | finanznachrichten.deSOLIGENIX, INC.: Soligenix Achieves Important Safety Milestone in its Confirmatory Phase 3 Clinical Trial of HyBryte for the Treatment of Cutaneous T-Cell LymphomaOctober 7, 2025 | finanznachrichten.deSoligenix stock soars after DMC confirms safety in Phase 3 CTCL studyOctober 7, 2025 | investing.comSoligenix Achieves Important Safety Milestone in its Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell LymphomaOctober 7, 2025 | prnewswire.comSoligenix (NASDAQ:SNGX) CEO Christopher Schaber Purchases 15,132 SharesOctober 4, 2025 | insidertrades.comSNGX: Public Offering Raises $7.5 Million; Expands European Medical Advisory BoardSeptember 30, 2025 | finance.yahoo.comSoligenix Announces Expansion of European Medical Advisory Board for Cutaneous T-Cell LymphomaSeptember 30, 2025 | prnewswire.comSoligenix Announces Closing of $7.5 Million Public OfferingSeptember 29, 2025 | prnewswire.comSoligenix stock tumbles after pricing $7.5 million public offeringSeptember 26, 2025 | za.investing.comSoligenix stock down after pricing $7.5M public offering to raise capitalSeptember 26, 2025 | msn.comSoligenix Announces Pricing of $7.5 Million Public OfferingSeptember 26, 2025 | prnewswire.comSoligenix Slumps Despite Word of New HireSeptember 24, 2025 | baystreet.caSoligenix Announces Appointment of Former White House Economic Adviser Tomas J. Philipson, PhD as Strategic AdvisorSeptember 23, 2025 | prnewswire.comSoligenix files to sell 2.91M shares of common stock, 2.91M warrantsSeptember 19, 2025 | msn.comSoligenix Tumbles After Company Publishes PaperSeptember 4, 2025 | baystreet.caSoligenix Announces Publication Describing Long-Term High Temperature Stability of Protein Subunit Vaccines for Ebola and Related VirusesSeptember 4, 2025 | prnewswire.comSoligenix Invited to Present at the H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 2, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines2 AI Stocks With Record Breaking Rallies: Can They Continue?By Dan Schmidt | September 29, 2025Tesla Earnings Loom: Bulls Eye $600, Bears Warn of $300By Sam Quirke | September 29, 2025Lowe’s vs. Home Depot: Which Benefits More From Lower Rates?By Dan Schmidt | October 8, 2025What Amazon's Chart Says a Week Before EarningsBy Sam Quirke | October 16, 20253 Overlooked Stocks Where Rewards Outweigh the RisksBy Nathan Reiff | October 20, 2025DMAC, ARDS, CPIX, LPTX, and SNGX Company DescriptionsAridis Pharmaceuticals NASDAQ:ARDS$0.0019 0.00 (-9.52%) As of 02:25 PM EasternAridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, discovers and develops targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that has completed Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin, as well as developing AR-301 as an adjunctive therapy with SOC antibiotics to treat hospital acquired pneumonia and ventilator associated pneumonia. The company is also developing AR-320, a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR 501, an inhaled gallium citrate, which is in Phase 1/2a for the treatment of chronic lung infection associated with cystic fibrosis; and AR-101, a human IgM mAb, which is in Phase II clinical trials targeting Pseudomonas aeruginosa liposaccharides serotype O11. In addition, it develops AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-701, a cocktail of two fully human immunoglobulin 1. The company was founded in 2003 and is headquartered in Los Gatos, California.Cumberland Pharmaceuticals NASDAQ:CPIX$3.64 +0.08 (+2.25%) Closing price 03:59 PM EasternExtended Trading$3.36 -0.28 (-7.69%) As of 05:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.DiaMedica Therapeutics NASDAQ:DMAC$6.62 -0.15 (-2.22%) Closing price 04:00 PM EasternExtended Trading$6.62 0.00 (-0.08%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.Leap Therapeutics NASDAQ:LPTX$0.49 -0.04 (-7.08%) Closing price 04:00 PM EasternExtended Trading$0.49 +0.01 (+1.52%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.Soligenix NASDAQ:SNGX$1.65 -0.05 (-2.94%) Closing price 04:00 PM EasternExtended Trading$1.66 +0.01 (+0.67%) As of 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia, Ib, and Ic clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Micron Stock Could Soar 35% on AI Memory Demand WesBanco Insiders Signal Confidence With Coordinated Buys Will D-Wave's European Expansion Keep Fueling the Rally? Navitas Soars 78% on NVIDIA Update: Is This Rally Sustainable? Louis Vuitton Earnings Show Luxury Bull Market Isn’t Done Yet Waymo’s Global Expansion Strengthens the Case for GOOGL Stock Broadcom Inks OpenAI Deal: Why It's A Huge Win for AVGO Stock Meta vs OpenAI: Is Sora a True Threat to Meta's Dominance? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
